Drug profile · INN
insulin icodec
AWIQLI
insulin icodec (AWIQLI) is a insulin receptor agonist. Route of administration: solution. Current US regulatory status: approved.
Drug details — insulin icodec
- US status
- approved
- Class
- Alimentary tract and metabolism (A10)
- Route
- SOLUTION
- Patents
- 0
- Programs
- 6
- Data quality
- 0.84
Quick answer
insulin icodec (AWIQLI) is a insulin receptor agonist. Route of administration: solution. Current US regulatory status: approved.
Key facts
Mechanism of action
Insulin receptor agonist
Primary target: Insulin receptor
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | approved | — |
| PMDA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is insulin icodec?
insulin icodec (AWIQLI) is a insulin receptor agonist. Route of administration: solution. Current US regulatory status: approved.
What is the brand name for insulin icodec?
AWIQLI is a marketed brand name for insulin icodec. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of insulin icodec?
insulin icodec has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.